IPO registrations (S-1, F-1) · Registrants
Serina Therapeutics, Inc.
- SEC CIK
- 1708599 · filings on EDGAR ↗
- Former names
- AgeX Therapeutics, Inc. (2017–2024)
- Registration
- Form S-1, first filed 2024-05-03, last 2026-08-24; 2 initial registrations, 2 amendments
- Outcome
- Declared effective 2024-07-09
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- AL
- Business address
- 601 GENOME WAY, SUITE 2001, Huntsville, AL 35806
- EIN
- 82-1436829
- Ticker
- SER (NYSE)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Serina Therapeutics, Inc. on the corporate pages
On this site
- Form 5500 plan sponsor: AGEX THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: AgeX Therapeutics, Inc. EXACT (CIK (EXACT))
- Lobbying client: SERINA THERAPEUTICS, INC. Fuzzy (name and state)
- SEC filer: AgeX Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2024-05-03 | S-1 | S-1 (registration) | Serina Therapeutics, Inc. | 0001493152-24-017773 ↗ |
| 2024-06-17 | S-1/A | S-1/A (amendment) | Serina Therapeutics, Inc. | 0001493152-24-024004 ↗ |
| 2024-07-03 | S-1/A | S-1/A (amendment) | Serina Therapeutics, Inc. | 0001493152-24-026232 ↗ |
| 2024-07-09 | EFFECT | EFFECT (declared effective) | Serina Therapeutics, Inc. | 9999999995-24-002102 ↗ |
| 2025-04-10 | EFFECT | EFFECT (declared effective) | Serina Therapeutics, Inc. | 9999999995-25-001074 ↗ |
| 2025-04-28 | EFFECT | EFFECT (declared effective) | Serina Therapeutics, Inc. | 9999999995-25-001269 ↗ |
| 2026-02-13 | EFFECT | EFFECT (declared effective) | Serina Therapeutics, Inc. | 9999999995-26-000582 ↗ |
| 2026-06-03 | EFFECT | EFFECT (declared effective) | Serina Therapeutics, Inc. | 9999999995-26-001872 ↗ |
| 2026-08-24 | S-1 | S-1 (registration) | Serina Therapeutics, Inc. | 0001493152-26-039910 ↗ |
| 2026-08-31 | EFFECT | EFFECT (declared effective) | Serina Therapeutics, Inc. | 9999999995-26-002840 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bailey Gregory | Director | 19 | 2018–2026 | ||
| Jenkins Annalisa | Director | 3 | 2018–2021 | ||
| Juvenescence Ltd | Director,TenPercentOwner; TenPercentOwner | 21 | 2018–2025 | ||
| MAULDIN JOHN F | Director | 4 | 2018–2019 | ||
| Mulroy Michael H. | Director | 3 | 2018–2019 | ||
| SEGALL JUDITH | Officer | Corporate Secretary; Director, Admin & Secretary; Director of Admin & Secretary | 4 | 2018–2021 | |
| SKIBSTED RUSSELL | Officer | Chief Financial Officer | 2 | 2018–2019 | |
| STERNBERG HAL | Officer | Vice President-Research | 3 | 2018–2021 | |
| WEST MICHAEL D | Director,Officer; Officer | Chief Executive Officer | 18 | 2018–2023 | |
| MALIK NAFEES NASEER | Officer | Chief Operating Officer | 3 | 2018–2021 | |
| MAY MICHAEL H | Director | 2 | 2019–2021 | ||
| Park Andrea Eun Jae | Officer | Chief Financial Officer | 2 | 2020–2021 | |
| Hackett Joanne M. | Director | 2 | 2022 | ||
| Juvenescence US Corp. | Director,TenPercentOwner | 1 | 2023 | ||
| Renondin Jean-Christophe | Director | 1 | 2023 | ||
| MINTZ STEVEN | Director | 6 | 2024 | ||
| Gross Remy | Director | 2 | 2024 | ||
| HARRIS J MILTON | Director | 2 | 2024 | ||
| LEDGER STEVEN A | Director,Officer | Chief Executive Officer; Interim CEO | 6 | 2024–2026 | |
| Marshall Richard Peter | Director | 5 | 2024–2026 | ||
| Moreadith Randall | Officer | Chief Scientific Officer | 38 | 2024–2026 | |
| Viegas Tacey | Officer | COO and Secretary | 1 | 2024 | |
| GILL SIMBA | Director | 3 | 2024–2026 | ||
| Tenjarla Srini | Officer | SVP, CMC & Formulation | 4 | 2024–2026 | |
| CURHAN GREGORY S | Officer | Chief Financial Officer | 3 | 2024–2026 | |
| WILSON KAREN J | Director | 6 | 2025–2026 | ||
| Venkatesan Jay | Director | 6 | 2025–2026 | ||
| Brannan Stephen K. | Director | 5 | 2025–2026 | ||
| Simon Farrell | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-03-22 | AgeX Therapeutics, Inc. | Biotechnology | $5,000,000 | $4,500,000 | 17 | 1 |
| 2018-08-27 | AgeX Therapeutics, Inc. | Biotechnology | Indefinite | $200,000 | 1 | 1 |
| 2018-06-21 | AgeX Therapeutics, Inc. | Biotechnology | $5,000,000 | $5,000,000 | 1 | 1 |
| 2018-01-31 | AgeX Therapeutics, Inc. | Biotechnology | $1,000,000 | $462,500 | 20 | 1 |
| 2017-07-10 | AgeX Therapeutics, Inc. | Biotechnology | $10,000,000 | $8,850,000 | 18 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.